Technical Analysis for ZNTL - Zentalis Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Historical ZNTL trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Overbought Stochastic | Strength | -6.04% | |
50 DMA Resistance | Bearish | -6.21% | |
Stochastic Sell Signal | Bearish | -6.21% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -6.21% | |
Doji - Bearish? | Reversal | -6.21% | |
Upper Bollinger Band Walk | Strength | -6.21% | |
Overbought Stochastic | Strength | -6.21% | |
Upper Bollinger Band Touch | Strength | -6.21% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -5.93% | |
200 DMA Support | Bullish | -5.93% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
200 DMA Support | about 3 hours ago | |
20 DMA Support | about 3 hours ago | |
Fell Below 20 DMA | about 4 hours ago | |
Down 10% | about 4 hours ago | |
60 Minute Opening Range Breakdown | about 4 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin Bunker on December 23, 2014 and is headquartered in New York, NY.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Hormones Epidermal Growth Factor Receptor Tyrosine Kinase Receptors Her2 Molecule Therapeutics Her2/Neu Estrogen Transcription Factors Antiestrogens Estrogen Receptor Metastatic Breast Cancer Receptor Positive Selective Estrogen Receptor Degraders
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Hormones Epidermal Growth Factor Receptor Tyrosine Kinase Receptors Her2 Molecule Therapeutics Her2/Neu Estrogen Transcription Factors Antiestrogens Estrogen Receptor Metastatic Breast Cancer Receptor Positive Selective Estrogen Receptor Degraders
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 61.29 |
52 Week Low | 23.25 |
Average Volume | 260,497 |
200-Day Moving Average | 41.68 |
50-Day Moving Average | 44.75 |
20-Day Moving Average | 39.64 |
10-Day Moving Average | 40.61 |
Average True Range | 2.82 |
ADX | 20.94 |
+DI | 24.21 |
-DI | 16.82 |
Chandelier Exit (Long, 3 ATRs ) | 37.01 |
Chandelier Exit (Short, 3 ATRs ) | 42.94 |
Upper Bollinger Band | 44.54 |
Lower Bollinger Band | 34.75 |
Percent B (%b) | 0.9 |
BandWidth | 24.68 |
MACD Line | -0.17 |
MACD Signal Line | -1.22 |
MACD Histogram | 1.0572 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 47.50 | ||||
Resistance 3 (R3) | 47.38 | 45.96 | 46.84 | ||
Resistance 2 (R2) | 45.96 | 44.95 | 46.01 | 46.62 | |
Resistance 1 (R1) | 44.75 | 44.33 | 45.36 | 44.87 | 46.40 |
Pivot Point | 43.33 | 43.33 | 43.63 | 43.38 | 43.33 |
Support 1 (S1) | 42.12 | 42.32 | 42.73 | 42.24 | 40.70 |
Support 2 (S2) | 40.70 | 41.70 | 40.75 | 40.48 | |
Support 3 (S3) | 39.49 | 40.70 | 40.26 | ||
Support 4 (S4) | 39.61 |